According to the Congressional Budget Office (CBO), enacting the bill would increase direct spending by about $18.7 billion and increase direct revenues by $26.2 billion, resulting in a net decrease in the deficit of $7.6 billion by 2029.
The Congressional Budget Office (CBO) has released its score of the Senate Committee on Health, Education, Labor, and Pensions’ proposed bill, S.1895, the Lower Health Care Costs Act. According to the CBO, enacting the bill would increase direct spending by about $18.7 billion and increase direct revenues by $26.2 billion, resulting in a net decrease in the deficit of $7.6 billion by 2029.
The proposed legislation comprises 5 elements: ending surprise medical bills, reducing the prices of prescription drugs, improving transparency in health care, improving public health, and improving the exchange of health information.
Among those sections, elements aimed at reducing drug prices would be responsible for a substantial share of the savings; the CBO says that these provisions would result in a net decrease in the deficit of $4.6 billion over the coming decade.
Key to reducing drug prices are several of the bill’s provisions that apply to generics and biosimilars. According to the CBO, some of these elements of the bill would allow generics and biosimilars to reach the market sooner, leading to a decline in federal spending on prescription drugs and subsidies for health insurance.
Provisions in this portion of the bill would allow the FDA to:
The CBO states that the section of the bill providing the right to sue over sample availability and removal of the requirement to share a risk management system would, on its own, account for more than $3.7 billion in savings over 10 years. This substantial reduction in the deficit would result, in part, from the ability of generics and biosimilars to reach the market 1 to 2 years earlier, on average.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.